Akero Therapeutics IncNASDAQ:AKRO
- LAST PRICE32.7300
- TODAY'S CHANGE (%)1.5300 (4.9038%)
- Bid / Lots32.1500/ 1
- Ask / Lots33.5000/ 5
- Open / Previous Close31.5500 / 31.2000
- Day Range
- 52 Week Range
- Volume824,695
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AKRO |
|---|---|---|
| 09:32 ET | 2774 | 31.55 |
| 09:33 ET | 7284 | 31.445 |
| 09:35 ET | 10450 | 31.5637 |
| 09:39 ET | 1401 | 31.1 |
| 09:42 ET | 100 | 31.25 |
| 09:44 ET | 100 | 31.245 |
| 09:46 ET | 350 | 31.12 |
| 09:48 ET | 418 | 31.045 |
| 09:50 ET | 2585 | 31.295 |
| 09:51 ET | 700 | 31.13 |
| 09:53 ET | 200 | 31.08 |
| 09:55 ET | 697 | 31.3 |
| 09:57 ET | 5806 | 31.3 |
| 10:00 ET | 5984 | 31.46 |
| 10:02 ET | 1051 | 31.42 |
| 10:04 ET | 1334 | 31.35 |
| 10:06 ET | 400 | 31.14 |
| 10:08 ET | 200 | 31.31 |
| 10:09 ET | 300 | 31.285 |
| 10:11 ET | 200 | 31.29 |
| 10:13 ET | 1298 | 31.19 |
| 10:15 ET | 1300 | 31.23 |
| 10:18 ET | 3510 | 31.32 |
| 10:20 ET | 2300 | 31.325 |
| 10:22 ET | 100 | 31.36 |
| 10:24 ET | 10451 | 31.24 |
| 10:26 ET | 9532 | 31.54 |
| 10:27 ET | 1424 | 31.37 |
| 10:29 ET | 600 | 31.28 |
| 10:31 ET | 800 | 31.29 |
| 10:33 ET | 1338 | 31.18 |
| 10:36 ET | 700 | 31.25 |
| 10:38 ET | 1200 | 31.27 |
| 10:40 ET | 800 | 31.31 |
| 10:45 ET | 1761 | 31.49 |
| 10:47 ET | 10921 | 31.43 |
| 10:49 ET | 2904 | 31.595 |
| 10:51 ET | 2315 | 31.52 |
| 10:54 ET | 1900 | 31.545 |
| 10:56 ET | 200 | 31.555 |
| 10:58 ET | 230 | 31.58 |
| 11:00 ET | 1459 | 31.47 |
| 11:02 ET | 600 | 31.5 |
| 11:03 ET | 300 | 31.47 |
| 11:05 ET | 600 | 31.4 |
| 11:07 ET | 200 | 31.385 |
| 11:09 ET | 1700 | 31.43 |
| 11:12 ET | 400 | 31.35 |
| 11:14 ET | 7004 | 31.55 |
| 11:16 ET | 1400 | 31.555 |
| 11:18 ET | 1403 | 31.49 |
| 11:20 ET | 200 | 31.505 |
| 11:23 ET | 500 | 31.51 |
| 11:25 ET | 1704 | 31.66 |
| 11:27 ET | 700 | 31.655 |
| 11:30 ET | 2400 | 31.845 |
| 11:32 ET | 650 | 31.89 |
| 11:34 ET | 2605 | 31.83 |
| 11:36 ET | 400 | 31.73 |
| 11:38 ET | 200 | 31.81 |
| 11:39 ET | 1931 | 31.815 |
| 11:41 ET | 902 | 31.83 |
| 11:43 ET | 7000 | 31.86 |
| 11:45 ET | 200 | 31.86 |
| 11:50 ET | 15876 | 31.935 |
| 11:52 ET | 800 | 31.935 |
| 11:54 ET | 2610 | 31.85 |
| 11:56 ET | 700 | 31.88 |
| 11:57 ET | 1100 | 31.94 |
| 11:59 ET | 1400 | 31.9 |
| 12:01 ET | 18813 | 31.95 |
| 12:03 ET | 2889 | 31.98 |
| 12:06 ET | 5210 | 32.005 |
| 12:08 ET | 905 | 31.96 |
| 12:10 ET | 33751 | 31.945 |
| 12:12 ET | 1000 | 31.945 |
| 12:14 ET | 900 | 31.885 |
| 12:15 ET | 8700 | 31.905 |
| 12:17 ET | 2900 | 32.02 |
| 12:19 ET | 1390 | 32.1 |
| 12:24 ET | 300 | 32.155 |
| 12:26 ET | 200 | 32.14 |
| 12:28 ET | 100 | 32.11 |
| 12:30 ET | 2326 | 32.14 |
| 12:32 ET | 1900 | 32.13 |
| 12:35 ET | 2664 | 32.085 |
| 12:37 ET | 300 | 32.13 |
| 12:44 ET | 2300 | 32.18 |
| 12:46 ET | 1111 | 32.1388 |
| 12:48 ET | 4043 | 32.165 |
| 12:50 ET | 1810 | 32.1468 |
| 12:51 ET | 3500 | 32.22 |
| 12:55 ET | 652 | 32.33 |
| 12:57 ET | 100 | 32.31 |
| 01:00 ET | 300 | 32.37 |
| 01:02 ET | 500 | 32.38 |
| 01:04 ET | 1186 | 32.375 |
| 01:06 ET | 500 | 32.39 |
| 01:09 ET | 700 | 32.35 |
| 01:11 ET | 1500 | 32.36 |
| 01:13 ET | 300 | 32.39 |
| 01:15 ET | 7500 | 32.375 |
| 01:18 ET | 1400 | 32.41 |
| 01:22 ET | 900 | 32.41 |
| 01:24 ET | 955 | 32.5 |
| 01:26 ET | 4597 | 32.52 |
| 01:27 ET | 202 | 32.54 |
| 01:29 ET | 300 | 32.58 |
| 01:31 ET | 1448 | 32.5499 |
| 01:33 ET | 1609 | 32.63 |
| 01:36 ET | 650 | 32.675 |
| 01:38 ET | 1400 | 32.72 |
| 01:40 ET | 2336 | 32.52 |
| 01:42 ET | 1807 | 32.405 |
| 01:44 ET | 1365 | 32.305 |
| 01:45 ET | 300 | 32.28 |
| 01:47 ET | 13600 | 32.31 |
| 01:49 ET | 200 | 32.36 |
| 01:54 ET | 920 | 32.35 |
| 01:56 ET | 3817 | 32.28 |
| 01:58 ET | 200 | 32.34 |
| 02:00 ET | 1100 | 32.385 |
| 02:02 ET | 1820 | 32.4199 |
| 02:03 ET | 1700 | 32.49 |
| 02:05 ET | 2958 | 32.51 |
| 02:07 ET | 321 | 32.52 |
| 02:09 ET | 1300 | 32.51 |
| 02:12 ET | 234 | 32.54 |
| 02:14 ET | 1316 | 32.51 |
| 02:16 ET | 2689 | 32.47 |
| 02:18 ET | 800 | 32.455 |
| 02:20 ET | 1800 | 32.45 |
| 02:21 ET | 1300 | 32.425 |
| 02:23 ET | 2400 | 32.495 |
| 02:25 ET | 2301 | 32.48 |
| 02:27 ET | 800 | 32.505 |
| 02:32 ET | 2954 | 32.57 |
| 02:34 ET | 1500 | 32.5975 |
| 02:36 ET | 2400 | 32.61 |
| 02:38 ET | 1300 | 32.66 |
| 02:39 ET | 2362 | 32.645 |
| 02:41 ET | 2100 | 32.62 |
| 02:43 ET | 2235 | 32.595 |
| 02:45 ET | 1292 | 32.62 |
| 02:48 ET | 200 | 32.57 |
| 02:50 ET | 1927 | 32.57 |
| 02:54 ET | 6109 | 32.69 |
| 02:56 ET | 4989 | 32.75 |
| 02:57 ET | 700 | 32.75 |
| 02:59 ET | 26440 | 32.725 |
| 03:01 ET | 3426 | 32.7 |
| 03:03 ET | 200 | 32.695 |
| 03:06 ET | 2672 | 32.645 |
| 03:08 ET | 1001 | 32.695 |
| 03:12 ET | 400 | 32.66 |
| 03:14 ET | 1876 | 32.63 |
| 03:15 ET | 200 | 32.65 |
| 03:17 ET | 500 | 32.67 |
| 03:19 ET | 2234 | 32.66 |
| 03:21 ET | 2689 | 32.66 |
| 03:24 ET | 4962 | 32.575 |
| 03:26 ET | 200 | 32.585 |
| 03:28 ET | 2095 | 32.62 |
| 03:30 ET | 800 | 32.58 |
| 03:32 ET | 5600 | 32.58 |
| 03:33 ET | 800 | 32.63 |
| 03:35 ET | 2662 | 32.75 |
| 03:37 ET | 1905 | 32.805 |
| 03:39 ET | 1000 | 32.83 |
| 03:42 ET | 1340 | 32.84 |
| 03:44 ET | 7505 | 32.8 |
| 03:46 ET | 1500 | 32.835 |
| 03:48 ET | 2300 | 32.85 |
| 03:50 ET | 4510 | 32.805 |
| 03:51 ET | 5952 | 32.76 |
| 03:53 ET | 6570 | 32.84 |
| 03:55 ET | 5794 | 32.9 |
| 03:57 ET | 13032 | 32.835 |
| 04:00 ET | 176254 | 32.73 |
Nov 18, 2024
DJ Akero Therapeutics Initiated at Buy by Citigroup, from 7:51AM ET on Monday Nov 18, 2024 by Dow Jones
7:51AM ET on Monday Nov 18, 2024 by Dow JonesDJ Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 7:42AM ET on Monday Nov 18, 2024 by Dow Jones
7:42AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 15, 2024
Nov 13, 2024
Akero Therapeutics to Present at the Jefferies London Healthcare Conference, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow JonesAttention Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf, from 1:02PM ET on Wednesday Nov 13, 2024 by Dow Jones
1:02PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Akero Therapeutics Inc | 2.2B | -8.7x | --- |
Keros Therapeutics Inc | 2.2B | -10.7x | --- |
CG Oncology Inc | 2.2B | -28.2x | --- |
Longboard Pharmaceuticals Inc | 2.3B | -26.7x | --- |
Soleno Therapeutics Inc | 2.4B | -17.4x | --- |
Centessa Pharmaceuticals PLC | 2.3B | -11.2x | --- |
Company Information
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing phase IIb SYMMETRY, phase III SYNCHRONY Histology, and phase III SYNCHRONY real-world studies. The phase III SYNCHRONY program builds on the results of two phase IIb clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. EFX is designed to offer convenient once-weekly dosing.
Contact Information
- Headquarters
- 601 Gateway Boulevard, Suite 350SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-487-6488
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Iwicki
- President, Chief Executive Officer, Director
- Andrew Cheng
- Chief Operating Officer, Executive Vice President, Secretary, Co-Founder
- Jonathan Young
- Chief Scientific Officer, Co-Founder
- Timothy Rolph
- Chief Financial Officer, Executive Vice President, Head - Corporate Development, Treasurer
- William White
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 69.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.24 |
EPS | $-3.75 |
Book Value | $9.60 |
P/E Ratio | -8.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
